Quick Answer
Eton Pharmaceuticals, Inc. reported Total Revenue of $79.95 million for fiscal year 2025.
Eton Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $79.95M +104.9% |
$39.01M +23.3% |
$31.64M +48.9% |
$21.25M -2.7% |
$21.83M +55879.5% |
$39.0K -95.9% |
| Revenue (ASC 606) | $79.95M +104.9% |
$39.01M +23.3% |
$31.64M +48.9% |
$21.25M -2.7% |
$21.83M +55879.5% |
$39.0K -95.9% |
| Net Income | -$4.60M -20.4% |
-$3.82M -308.4% |
-$936.0K +89.6% |
-$9.02M -361.4% |
-$1.96M +93.0% |
-$27.97M -52.7% |
| Total Assets | $92.11M +21.0% |
$76.12M +139.8% |
$31.74M +26.8% |
$25.03M -8.9% |
$27.46M +4.4% |
$26.32M +54.2% |
| Cash and Equivalents | $25.94M +73.7% |
$14.94M -30.2% |
$21.39M +31.2% |
$16.30M +13.2% |
$14.41M -32.4% |
$21.30M +76.5% |
| Long-Term Debt | $21.77M -27.0% |
$29.81M | $0.00 -100.0% |
$5.38M +2.3% |
$5.26M -19.4% |
$6.53M +43.9% |
| Stockholders Equity | $26.15M +7.1% |
$24.43M +57.8% |
$15.48M +18.3% |
$13.08M -25.8% |
$17.63M +0.0% |
$17.63M +67.1% |
| R&D Expense | $7.76M +138.6% |
$3.25M -2.0% |
$3.32M -16.9% |
$4.00M -35.9% |
$6.24M -55.8% |
$14.10M +22.1% |
| Operating Income | -$844.0K +67.5% |
-$2.60M -117.9% |
-$1.19M +85.6% |
-$8.26M -452.5% |
-$1.50M +94.5% |
-$27.11M -45.8% |
| Gross Profit | $42.74M +82.6% |
$23.41M +11.2% |
$21.06M +47.1% |
$14.32M -24.7% |
$19.00M +4887.2% |
-$397.0K -178.5% |
| Shares Outstanding | 27.05M +1.3% |
26.71M +4.0% |
25.69M +1.3% |
25.35M +3.0% |
24.63M +1.3% |
24.31M +36.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $22.46M | +117.5% | +18.7% |
| Revenue (ASC 606) | September 30, 2025 | $22.46M | +117.5% | +18.7% |
| Net Income | September 30, 2025 | -$1.93M | -407.3% | +25.5% |
| Diluted EPS | September 30, 2025 | -$0.07 | -450.0% | -450.0% |
| Total Assets | September 30, 2025 | $104.51M | +191.6% | +2.8% |
| Cash and Equivalents | September 30, 2025 | $37.12M | +83.2% | +46.3% |
| Long-Term Debt | September 30, 2025 | $27.59M | — | +0.7% |
| Stockholders Equity | September 30, 2025 | $23.13M | +44.7% | -3.5% |
| R&D Expense | September 30, 2025 | $1.11M | +120.2% | -70.0% |
| Operating Income | September 30, 2025 | -$1.36M | -367.8% | +7.6% |
| Gross Profit | September 30, 2025 | $7.86M | +24.6% | -34.1% |
| Shares Outstanding | September 30, 2025 | 26.82M | +3.8% | +0.0% |
- Eton Pharmaceuticals, Inc. reported Total Revenue of $79.95 million for fiscal year 2025.
- Eton Pharmaceuticals, Inc. showed an increase of +104.9% in Total Revenue compared to the prior fiscal year.
- Eton Pharmaceuticals, Inc. reported Revenue (ASC 606) of $79.95 million for fiscal year 2025.
- Eton Pharmaceuticals, Inc. showed an increase of +104.9% in Revenue (ASC 606) compared to the prior fiscal year.
- Eton Pharmaceuticals, Inc. reported Net Income of -$4.60 million for fiscal year 2025.
- Eton Pharmaceuticals, Inc. showed a decrease of -20.4% in Net Income compared to the prior fiscal year.
- Eton Pharmaceuticals, Inc. reported Total Assets of $92.11 million for fiscal year 2025.
- Eton Pharmaceuticals, Inc. showed an increase of +21.0% in Total Assets compared to the prior fiscal year.
- Eton Pharmaceuticals, Inc. reported Cash and Equivalents of $25.94 million for fiscal year 2025.
- Eton Pharmaceuticals, Inc. showed an increase of +73.7% in Cash and Equivalents compared to the prior fiscal year.
- Eton Pharmaceuticals, Inc. reported Long-Term Debt of $21.77 million for fiscal year 2025.
- Eton Pharmaceuticals, Inc. showed a decrease of -27.0% in Long-Term Debt compared to the prior fiscal year.
- Eton Pharmaceuticals, Inc. reported Stockholders Equity of $26.15 million for fiscal year 2025.
- Eton Pharmaceuticals, Inc. showed an increase of +7.1% in Stockholders Equity compared to the prior fiscal year.
- Eton Pharmaceuticals, Inc. reported R&D Expense of $7.76 million for fiscal year 2025.
- Eton Pharmaceuticals, Inc. showed an increase of +138.6% in R&D Expense compared to the prior fiscal year.
- Eton Pharmaceuticals, Inc. reported Operating Income of -$844.0 thousand for fiscal year 2025.
- Eton Pharmaceuticals, Inc. showed an increase of +67.5% in Operating Income compared to the prior fiscal year.
- Eton Pharmaceuticals, Inc. reported Gross Profit of $42.74 million for fiscal year 2025.
- Eton Pharmaceuticals, Inc. showed an increase of +82.6% in Gross Profit compared to the prior fiscal year.
- Eton Pharmaceuticals, Inc. reported Shares Outstanding of 27.05 million shares for fiscal year 2025.
- Eton Pharmaceuticals, Inc. showed an increase of +1.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: